Sera Prognostics Predicts Clinical Utility of Preterm Test-and-Treat Strategies
Sera Prognostics’ blood-based test offers individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Read MorePosted by Andy Lundin | Nov 16, 2022 | Prenatal Testing |
Sera Prognostics’ blood-based test offers individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Read MorePosted by Chris Wolski | Nov 14, 2022 | Diagnostic Technologies |
Clinical laboratory experts predict continued importance on COVID testing, ongoing technician shortages, and more in 2023.
Read MorePosted by Chris Wolski | Nov 14, 2022 | Immunoassay Reagents & test Kits |
PerkinElmer has announced that the FDA has authorized the marketing of the EONIS SCID-SMA assay kit for the diagnosis of SMA and SCID.
Read MorePosted by Chris Wolski | Nov 11, 2022 | Prenatal Testing |
Cedars-Sinai investigators have found that a specific imbalance of two placental proteins could predict preeclampsia risk.
Read MorePosted by Chris Wolski | Nov 9, 2022 | Biochemicals & Chemical Reagents |
PCR Biosystems has launched a new family of qPCR reagents mixes: Clara Probe Mix, Clara Probe 1-Step Mix and Clara HRM Mix.
Read More